

CORRECTION

# Correction: HP1 $\beta$ Is a Biomarker for Breast Cancer Prognosis and PARP Inhibitor Therapy

Young-Ho Lee, Xiyong Liu, Fuming Qiu, Timothy R. O'Connor, Yun Yen, David K. Ann

There are errors in the Funding section. The correct funding information is as follows: This work was supported by National Institute of Health Research Grants R01DE10742 and R01DE14183, and The Mary Kay Foundation Research Grant number 005–13 (to DKA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Reference

1. Lee Y-H, Liu X, Qiu F, O'Connor TR, Yen Y, Ann DK (2015) HP1 $\beta$  Is a Biomarker for Breast Cancer Prognosis and PARP Inhibitor Therapy. PLoS ONE 10(3): e0121207. doi:[10.1371/journal.pone.0121207](https://doi.org/10.1371/journal.pone.0121207) PMID: [25769025](https://pubmed.ncbi.nlm.nih.gov/25769025/)



## OPEN ACCESS

**Citation:** Lee Y-H, Liu X, Qiu F, O'Connor TR, Yen Y, Ann DK (2015) Correction: HP1 $\beta$  Is a Biomarker for Breast Cancer Prognosis and PARP Inhibitor Therapy. PLoS ONE 10(4): e0124853. doi:[10.1371/journal.pone.0124853](https://doi.org/10.1371/journal.pone.0124853)

**Published:** April 13, 2015

**Copyright:** © 2015 Lee et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.